Dupilumab is the first US FDA approved biologic for treatment of atopic dermatitis. It is a human monoclonal antibody which blocks the shared receptor component, the interleukin (IL)-4α subunit, of IL-4 and IL-13 signaling pathways. Occurrence of "conjunctivitis", mostly in atopic dermatitis trials, has been the main side effect reported thus far. The etiology of "conjunctivitis" associated with dupilumab treatment is unclear and might be similar to atopic keratoconjunctivitis. There is evidence in the published literature that unlike the Th2-like profile in vernal keratoconjunctivitis, Th1-mediated inflammation is predominant in atopic keratoconjunctivitis. Blocking the Th2 pathway with dupilumab therapy might result in a shift towards Th1,.causing the ocular findings associated with dupilumab. In addition, blockage of IL-13 might have implications with regards to mucin production and ocular surface health. This review highlights the clinical manifestations, reviews treatment options and offers explanations for pathogenesis of this ocular surface diseases associated with dupilumab treatment.

中文翻译：

---

与dupilumab治疗异位性疾病有关的眼表疾病。

Dupilumab是首个获得美国FDA批准用于治疗特应性皮炎的生物制剂。它是一种人类单克隆抗体，可阻断IL-4和IL-13信号通路的共享受体成分，即白介素（IL）-4α亚基。迄今为止，“结膜炎”的发生（主要在特应性皮炎试验中）是主要的副作用。与dupilumab治疗相关的“结膜炎”的病因尚不清楚，可能与特应性角膜结膜炎相似。在已发表的文献中有证据表明，与春季角膜结膜炎中的Th2类特征不同，Th1介导的炎症在特应性角结膜炎中占主导地位。用dupilumab治疗阻断Th2通路可能会导致向Th1转移，从而导致与dupilumab相关的眼部发现。此外，IL-13的阻断可能对粘蛋白产生和眼表健康有影响。这篇综述突出了临床表现，综述了治疗选择，并为与dupilumab治疗相关的眼表疾病的发病机理提供了解释。